Candesartan Versus Propranolol for Migraine Prevention

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00884663

First Posted: April 21, 2009

Last Update Posted: December 24, 2013

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Collaborators:

AstraZeneca

St. Olavs Hospital

Kragerø Tablettproduksjon as, Norway

Information provided by (Responsible Party):

Norwegian University of Science and Technology

Purpose

The main aim of the present study is to compare candesartan with propranolol for migraine prophylaxis.

Condition	Intervention	Phase
Migraine Without Aura Migraine With Aura Chronic Migraine	Drug: Candesartan Drug: propranolol Drug: placebo	Phase 2 Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Crossover Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study

Resource links provided by NLM:

Genetics Home Reference related topics: familial hemiplegic migraine sporadic hemiplegic migraine

MedlinePlus related topics: Headache Migraine

Drug Information available for: Propranolol hydrochloride Propranolol Candesartan Candesartan cilexetil

U.S. FDA Resources

Further study details as provided by Norwegian University of Science and Technology:

Primary Outcome Measures:

The number of days per 4 weeks with moderate or severe headache lasting ≥ 4 hours or is treated with the patient's usual headache medication [ Time Frame: One year ]

Secondary Outcome Measures:

Days with headache [ Time Frame: One year ]
Hours with headache [ Time Frame: One year ]
Headache intensity (0-3 scale) on days with headache [ Time Frame: one year ]
Doses of analgesics [ Time Frame: one year ]
Doses of triptans [ Time Frame: One year ]
Days with sick leave [ Time Frame: one year ]
Number of responders (≥ 50% decrease in migraine days compared with baseline) [ Time Frame: one year ]
Number of reported side effects [ Time Frame: one year ]
Number of predefined retrospective side effects [ Time Frame: one year ]


Enrollment:	72
Study Start Date:	April 2009
Study Completion Date:	March 2012
Primary Completion Date:	March 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 Candesartan	Drug: Candesartan Candesartan cilexitil tablets, 16 mg once daily
Active Comparator: 2 propranolol	Drug: propranolol Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
Placebo Comparator: 3 Placebo	Drug: placebo placebo tablets and capsules

Detailed Description:

Candesartan was shown to be effective for migraine prophylaxis in a randomized double blind cross-over study published in 2003. The drug is now widely used for this purpose in many countries, although no confirmatory study has been published. The aims of the present study are: 1) to see if the results in the first candesartan study can be replicated in a new patient population, including patients with chronic migraine, and, 2) to perform a head-to-head comparison of candesartan 16 mg/day with standard treatment with propranolol 160 mg slow release. We also intend to study whether responsiveness to these drugs may be related to heart rate variability and baroreceptor sensitivity.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

age 18 to 65 years
retrospectively have ≥ 2 migraine attacks per month during the last 3 months
during the baseline period have ≥ 2 migraine attacks
debut of migraine at least one year prior to inclusion
start of migraine before age 50 years.

Exclusion Criteria:

interval headache not distinguishable from migraine
chronic tension-type headache or other headache occurring on ≥ 15 days/month
pregnancy, nursing or inability to use contraceptives
heart conduction block on ECG or significant ECG abnormality on inclusion
heart rate < 54 after 3 minutes rest
previous or present asthma, diabetes; decreased hepatic or renal function
hypersensitivity to active substance
history of angioneurotic edema
significant psychiatric illness
use of daily migraine prophylactics less than 4 weeks prior to start of study
having tried ≥ 3 prophylactic drugs against migraine during the last 10 years
previous use of propranolol or candesartan in adequate doses
previous discontinuation of either Atacand or Inderal Retard (or another beta blocker) due to side effects
current use of antihypertensive medication
require use of rizatriptan (Maxalt) 10 mg tabl.
subjects requiring detoxification from acute medication (ergotamines, opioids)
patients who consistently fail to respond to any acute migraine medication
patients with alcohol or illicit drug dependence

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00884663

Locations


Norway
Norwegian National Headache Centre, St. Olavs University Hospital
Trondheim, Norway, 7489

Sponsors and Collaborators

Norwegian University of Science and Technology

AstraZeneca

St. Olavs Hospital

Kragerø Tablettproduksjon as, Norway

Investigators


Principal Investigator:	Lars J Stovner, Ph.D.	Norwegian National Headache Centre, St. Olavs Hospital
Study Director:	Lars J Stovner, Ph.D.	Norwegian National Headache Centre

More Information

Publications:

Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, Hagen K. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014 Jun;34(7):523-32. doi: 10.1177/0333102413515348. Epub 2013 Dec 11.

Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003 Jan 1;289(1):65-9.


Responsible Party:	Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:	NCT00884663 History of Changes
Other Study ID Numbers:	01-47-7006-2008 2008-002312-17 ( EudraCT Number )
First Submitted:	April 20, 2009
First Posted:	April 21, 2009
Last Update Posted:	December 24, 2013
Last Verified:	December 2013

Additional relevant MeSH terms:


Migraine Disorders Migraine with Aura Migraine without Aura Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Propranolol Candesartan Candesartan cilexetil	Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Vasodilator Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists

To Top